ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences sector, has announced its acquisition of IntiQuan AG, a Swiss firm specializing in pharmacometric services for biopharmaceutical companies. This strategic acquisition further strengthens PLG’s offerings in drug development by adding advanced pharmacometric capabilities to its portfolio.
IntiQuan, founded in 2015 by Dr. Henning Schmidt, has earned a reputation for providing cutting-edge pharmacometric and statistical modeling services. These services help biopharmaceutical companies reduce development risks, costs, and timelines while enhancing patient safety through precise dose-response analysis and predictive safety profiling.
Enhanced Service Offerings for Drug Development
With the integration of IntiQuan, PLG now offers a wider range of specialized pharmacometrics services, including pharmacokinetics/pharmacodynamics (PK/PD) analysis, population pharmacokinetics (popPK), and biosimulation. IntiQuan’s expertise in translating complex data into actionable insights spans from pre-clinical trials to Phase IV studies, across multiple therapeutic areas. By leveraging advanced mathematical modeling and simulation, IntiQuan informs clinical trial designs and predicts outcomes, helping companies make data-driven decisions.
A Step Toward Global Expansion
The acquisition of IntiQuan aligns with PLG’s long-term strategy of creating a fully integrated global platform. With additional plans for expansion across the U.S. and European markets, PLG is working toward becoming a leading global provider of comprehensive drug development services.
Leadership Perspective on the Acquisition
Xavier Duburcq, CEO of PLG, highlighted the significance of the acquisition, stating, “We are excited to welcome the IntiQuan team to PLG. Their deep expertise in pharmacometrics and clinical pharmacology enhances the support we provide to clients during their drug development journey. Model-informed drug development offers insights that can impact key decisions and accelerate clinical development, even eliminating the need for certain trials.”
Dr. Henning Schmidt, Founder of IntiQuan, also expressed enthusiasm about the collaboration, saying, “Joining forces with PLG is a pivotal moment for IntiQuan. Together, we can reduce time to market and the cost of research and development through our combined solutions. We are thrilled to contribute to PLG’s global platform.”
Dr. Stefan Wetzel, CEO of IntiQuan, added, “Our organizations share a strong cultural alignment, focusing on high-quality, innovative, and customer-focused solutions. We look forward to offering an expanded set of complementary services, including regulatory support.”
Future of Drug Development
The acquisition of IntiQuan positions PLG to deliver enhanced pharmacometrics services, enabling biopharmaceutical companies to develop drugs more efficiently and safely. With this expanded capability, PLG is set to play a key role in shaping the future of drug development.
